Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06897475 | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | PHASE2 | RECRUITING | 240 | — | — | Mar 28, 2025 | Jan 1, 2027 | May 22, 2026 | 60 | United States, Canada +4 |
| Arm | Type | Description |
|---|---|---|
| LY3457263 Dose 1 | EXPERIMENTAL | Participants will receive LY3457263 subcutaneously (SC) |
| LY3457263 Dose 2 | EXPERIMENTAL | Participants will receive LY3457263 SC |
| LY3457263 Dose 3 | EXPERIMENTAL | Participants will receive LY3457263 SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Name | Type | Description |
|---|---|---|
| LY3457263 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have type 2 diabetes * Have HbA1c ≥7.5% to ≤10.5% at screening * Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening * Have had a stable body weight for the three months prior to screening * On stable treatment dose of one of the following incre...